## 

## 



## 

## 

## 

## 

## 

## 



## 

## 

## 



## 

|Report ofthe trustees||4 —27|
|---|---|---|
|Report ofthe independent<br>auditor||28 —31|
|Principal accounting|policies|32-34|
|Statement offinancial|activities|35 —36|
|Balance sheet||37|
|Statement ofcash flows||38|
|Notes to the financial|statements|39 -53|





## 

## 

## 

## 

## 

## 

## 



## 

## 

## 

## 



## 

## 

## 

## 

## 



## 

## 

## 



|The Psoriasis Association||
|---|---|
|Financial statements<br>for the year ended 31 December 2020||
|Report ofthe trustees<br>(continued)||
|Promote and Fund Research (continuedj||
|The Psoriasis Association<br>received a further two bound PhD theses to add to their library|during|
|2020, from:<br>Student —Marika Catapano.<br>Supervisor —Dr Francesca Capon (King's College Londonj-||
|Cbarasreri sation ofnwe!pathogenic pathwccys forgeon alisedpustular psoriasis||
|Student —Jemma Paterson.<br>Supervisor —Dr Tim Migar (University ofSouthamptonj —Nojtost||
|skin deep: circulating<br>hpidsin a 'localiwed'disease||
|Ongoing PhD Studentships<br>induded-||
|Dr Paola Di Meglio at King's College London,<br>Idenujiing<br>immune<br>ikterms'nants<br>ofclim'cul response to||
|suteksnumab<br>inpsoriasii||
|Dr Danide Bergamaschi at Queen Mary University ofLondon,<br>Impact ofautophagy<br>and nurieophagy||
|deregulation inpsoriasis||
|Professor Nick Reynolds at Newcastle<br>University,<br>Inoestigating<br>genetic cvntml ofthe psoniaiii||
|transcriPtome<br>to define and salidate<br>drug and disease endobiPes||
|Dr Henning<br>Hoge at the University ofHull, An attenti onal bias approach<br>to undersuindi<br>ng and irducing||
|the psycbosoa'al bunkn ofpsori uru||
|Dr Helen Young at the University ofManchester,<br>Inoestigating<br>the therapeutk<br>benefits ofexenue|sn|
|patients<br>neith psoriasis<br>Dr Francesca Capon at King's College London,<br>The role ofIL-1 and IL-36 s'n Pabuar Plantar||
|Plistuloiis<br>IPPP)<br>Professor Eugene Healy at the University ofSouthampton,<br>Mutation<br>burckn ofnarms band UVB||
|Professor Richard Wanen at the University ofManchester,<br>The risk ofcancrriripsoriasispatients||
|teated with biologic therapies<br>mmpared<br>ioith coniristiona! systemic therapies:<br>results fiom BADBIR||
|Dr Elise Kleyn at the Univetsity ofManchester,<br>Neusvpsycho<br>logical<br>morbidity<br>inpsoriaris||
|DrJulian Knight at Oxford University,<br>Functional characterisation<br>ofgenetic suscrptibi<br>ilty topsoriasis||
|Professor Silvia BulfonePaus<br>at the University ofManchester,<br>The mk ofmast cell trfptme in|psoriatic|
|itch<br>psoriasis||
|There were four ongoing<br>small grants-||
|Dr Henry Grantham<br>at the Royal Victoria Infinuary,<br>Newcastle, Apslot study to sampan<br>the|msponse|
|ofpsorimis<br>to narrow-band<br>UVBphototherapy<br>in the morning<br>and afi'ernoon||
|Dr Elise Kleyn at the University ofManchester, An iemooati re mixed methods<br>studp inoestigating|altered|
|emotionalprvcessingin<br>patient||
|Dr Parastoo Babakinejad<br>at the Royal Victoria Infirmary,<br>Newcastle,<br>Investigation<br>ofthe pres abner of||
|lirerfibmsu inpatients uith psoriasis ming Traiisi eat Elastographsi<br>and eoaluation ofthe srhstionship<br>between||
|liverfibrosis and methotrexate||
|Ms Ella Guest at the University ofthe West ofEngland,<br>Theimpact offkire ups onpsycbokgicat|uell-|
|bnng,<br>trmtment<br>adherents,<br>and hfe engagementinpeopk<br>bring uith psoriasis.<br>Ms Guest's project was<br>completed<br>in 2020 and the final results have been published<br>on the Psoriasis Association<br>website||
|and in Pso.||
|The COVID-19 pandemic<br>caused wet laboratory<br>work to be suspended<br>for a number ofmonths||
|in 2020 and has resulted<br>in delays in progression<br>for many ofour research projects. Due to the<br>pandemic,<br>six grant extensions<br>have been requested<br>and granted to ensure the completion ofthe||
|research projects. These consisted ofEve no-cost extensions<br>and one costed extension to|cover|
|the student<br>stipend<br>during the three-month<br>extension.<br>The coated extension was granted|after|
|special consideration<br>by Psoriasis Association Trustees.<br>Artides authored<br>by sponsored PhD Students were published<br>in the Following journals in|2020;|
|British Journal ofDermatology,<br>JAMA Dermatology.||
|Letters bringing<br>attention to the 2020 call for applications<br>were sent to aBDermatology<br>and<br>Rheumatology<br>Departments<br>in the United Kingdom,<br>the Deans ofaB Medical Schools in the||
|United Kingdom, in addition to the Deans ofaBHealth Schools in the United Kingdom<br>and<br>Heads ofaBHealth Service Research Centres.<br>Contact was made with the British Association of||
|Dennatologists<br>and the British Dermatological<br>Nursing<br>Group in order to bring their members||
|attention to the caB. The Psoriasis Association Twitter and LinkedIn accounts were used|to|
|target aletts throughout<br>the caBto healthcare<br>professionals,<br>researchers<br>and relevant||
|organisations.||





## 

## 



## 

## 



## 

## 



## 

## 

## 

## 

## 



## 

## 



## 

## 



## 

## 



## 

## 

## 

## 



## 



## 



## 

## 

## 

## 



## 

## 

## 



## 

## 



## 

## 

## 

## 

## 



## 

## 

## 

## 

## 



## 

## 

## 



## 

## 

## 



## 

## 

## 



## 

## 

## 

## 

## 



## 

## 

## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 

## 

## 



## 


## 

## 



## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 

## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 

## 

## 

## 

## 



|||0|0<br> O|||||||C<br>0||||||o|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|||lr o <br>8 N<br>0Orr||'QS|||ChO<br>Ql|o|lflr<br>d<br> r|QQI0<br>Cl||QQ <br>e|o<br>O<br> rlfl||||
||||||||I<br>Q0<br>e4'|O<br>I<br> o"|I|||||Ql|||
||||rl040||||||||||||||
||||Ct||||||||||||||
|||||||||||||||QQ||QQ|
|||||||||||||||Cl<br>Ih||Cl<br>ltl|
|ONON||C|P.<br>0||||e <br>ef|r <br>'tr<br> 0|~tl<br> r<br>0|||+ <br>CiQ|O<br> ttl<br>rQ|ltd|||
|||||||||||||0|0||||
|||||rl|||||||||||||
|||||0|||||||||||||
|IQ|||||||||||||||||
|0|cQi||||||||||||||||
|QI|cubi||||||||||||||||
|0|V||||||||||||||||
|g9<br>0<br>V<br>„E<br>0<br>PJ<br>lr|||||QS|0<br> B|5<br>-„8<br>VSQ 6<br>QC8|||0'0<br>C<br>'0<br>C<br>C|C0<br>C<br>0||||li<br>0<br>0<br>L||
|i|||||C|aa||0|C||rr||||z||





## 

## 

## 

|||Note||||2019|
|---|---|---|---|---|---|---|
|Fixed assets|||||||
|Tangible 6xed assets||||495,000||500,000|
|Investments||||5,6D5 140||5,186,247|
|||||6,100,148||5,686,247|
|Current assets|||||||
|Debtors||10|28,334||54,722||
|Cash at bank and in|hand||1887,509||815,985||
||||1@15,843||870,707||
|Cteditors: amounts|falling due||||||
|within one year|||90,983||80,939||
|Net current assets||||1,224,860||789,768|
|Total assets less current liabilities||||7425,008||6476,015|
|Capital funds<br>Endowments||13||4,489,953||4,040,478|
|Income funds|||||||
|Restricted<br>funds||14||685,298||688,231|
|Unrestricted<br>funds:|||||||
|Property<br>fund<br>General funds||||495,000<br>412,810||500,000<br>399,673|
|Designated<br>funds||15||1+41,947||847,633|
|||||7426.DDD||6,476,015|





## 

|||Note|2020|2019|
|---|---|---|---|---|
|Net cash generated/(used)<br>activities|from operating|17|423,200|(342,131)|
|Cash flows &orninvesnng<br>Interest received|acrivifles:||77870|8,406|
|Investment<br>income received|||101,972|125,908|
|Purchase ofinvestments|||(1,120,877)|(1,338,790)|
|Sale ofinvestments|||1&059359|1,432,885|
|Net cash provided<br>by investing<br>activities|||48@24|228,409|
|Change in cash and cash|equivalents<br>in the year||471,524|(113,722)|
|Cash and cash equivalents<br>brought<br>forward|||815,985|929,707|
|Cash and cash equivalents|carried forward||&&8&5» ,|81», 85|





## 

## 

## 

|Donations<br>and leffacies||||
|---|---|---|---|
|||2020|2019|
|Membership<br>subscriptions<br>—individual||36,865|36,499|
|—corporate<br>Gift Aid from subscriptions|and donations|11,850<br>11,094|8,750<br>11,166|
|Donations<br>from Charitable|Trusts|1&100|5,600|
|Donations<br>in memoriam||7,001|8,029|
|Other donations||16,715|18,160|
|Legacies (see below)<br>Bank interest receivable||839,173<br>68|328,306<br>80|
|Fundraising<br>income donated|by individuals|22,225|24,597|
|||946,091|441,187|



|Legacies received during the year are as follows:|||
|---|---|---|
||2020|2019|
|Monty Chems<br>Anne Gadd||12,297<br>53,312|
|Susan Jayne Larby<br>Kathryn<br>Sylvia Brookes||21,094<br>20,000|
|John Michael Naden||8,035|
|Edith Mary Taylor<br>Elaine Constance Warner||12,651<br>16,139|
|Dorothy Whitdey<br>Sydney Leonard Brown<br>Patrick Douglas WaBace|112,833|10,000<br>10,000<br>160,278|
|Richatd Charles Longfteld|172@06||
|Margaret Elizabeth<br>Sail|180,884||
|Sheila Poynter<br>Margaret Ann Clark<br>Other|210,258<br>150,000<br>12,892|4,500|
||039,173|338,306|





## 

## 

## 

## 

|Investment<br>income compris|es income fro|m:|||
|---|---|---|---|---|
||||2020|2019|
|Listed investments|||101,972|125,908|
|Bank deposits|||7,870|8,406|
||||159,542|134,314|
|Income from charitable|activities||||
||||2020|2019|
|Corporate sponsorship<br>Trust donations|||63,000<br>1,000|12,380<br>1,000|
|Bank interest receivable|||68|80|
|Journal advertising<br>Annual Conference/AGM|and Awareness|week|1,280|2,840<br>2,555|
|Reunbursements|||4,000|3,000|
|Other|||5,227|3,416|
||||74,575|25,271|



## 

|Analysis of total|res|ourc|es expended|||||
|---|---|---|---|---|---|---|---|
|||||||Total|Total|
|||||Staffcosts|Othet|2020|2019|
|Raising funds:<br>Costs ofgenerating<br>voluntary<br>income<br>Investment<br>management<br>costs||||48,919|14,953<br>31,447|63,872<br>31,447|59,238<br>33,651|
|Charitable<br>activities:||||||||
|Charitable<br>activities||||177,736|313,148|4903884|571,162|
|Governance<br>costs||||32,360|15@35|47,695|57,108|
|Tl||||259,015|374,883|633,898|721,159|





## 

## 

## 

## 

## 

## 

|Analysis oftotal reso|urces expended<br>(continued)|urces expended<br>(continued)|||
|---|---|---|---|---|
|Total resources expended|include:||||
||||2020|2019|
|Raising funds<br>Rent and rates|||185|190|
|Heat and light<br>Phone and fax|||529<br>388|552<br>183|
|Internet<br>and email|||437|432|
|Office insurance|||371|335|
|Hire/repair<br>and maintenance<br>Professional<br>fees||ofequipment|502<br>85|514<br>82|
|Bank charges<br>Computer<br>costs<br>Printing<br>and stationery<br>Annual report<br>Post and carriage|||1,097<br>1,075<br>909<br>1473<br>539|1,190<br>1,181<br>809<br>1,214<br>500|
|Fundraising<br>costs<br>Website|||1,750<br>237|3,070<br>407|
|Subscriptions|||1,114|965|
|Sundries|||73|93|
|Ofhce equipment<br>Property maintenance<br>Designated<br>fund (development)|||222<br>736<br>3r331|154<br>950<br>1,517|
||||14,953|14,338|
|Investment<br>Management||Costs|31,447|33,651|
|Charitable<br>activities|||||
|Grants payable<br>Rent and rates|||246,416<br>556|209,814<br>570|
|Heat and light<br>Phone and fax|||1,588<br>1,551|1,657<br>733|
|Internet<br>and email|||1,747|1,728|
|Office insurance|||1113|1,004|
|Hire/repair<br>and maintenance<br>Professional<br>fees||ofequipment|1,505<br>154|1,541<br>150|
|Bank charges<br>Computer<br>costs<br>Printing<br>and stationery<br>Printing<br>educational<br>Annual report<br>Journals<br>and postage<br>Post and carriage|||1,097<br>1,076<br>2,728<br>792<br>2,745<br>7,725<br>2,154|1,190<br>1,181<br>2,426<br>645<br>2,429<br>8,557<br>2,000|





## 

## 

## 

## 

## 

## 

|nalysis oftotal resource|s expended<br>(continued)|||
|---|---|---|---|
|||2020|2019|
|Brought forward<br>Staff Recruiunent||272,947|235,625<br>638|
|Advertising<br>and promotion<br>Website||23112<br>948|7,804<br>1,628|
|Travel and subsistence||138|1,787|
|Meetings<br>and conferences|||1,285|
|AGM costs|||6,767|
|Grant Management<br>Subscriptions<br>Sundries||1/16<br>1,114<br>142|1,955<br>964<br>171|
|Office equipment<br>Property maintenance<br>Designated<br>fund (staff training)<br>Designated<br>fund (promotion<br>and education)||222<br>2,577<br>1,166<br>1DP20|154<br>3,326<br>4,210<br>18,516|
|Designated<br>fund<br>(504s Anniversary)<br>Designated<br>fund (development)<br>Designated<br>fund (research)||4,860<br>10+80|129,001<br>930<br>19,848|
|Sponsored projects<br>Scotland||4,451<br>555|609|
|||313,148|435,218|
|Governance<br>costs||||
|Trustees insurance||847|768|
|Auditor's<br>remuneration<br>—audit services||10,843|15,018|
|Surveyor<br>fees<br>Annual report<br>Travel and subsistence||600<br>457<br>393|840<br>405<br>956|
|Legal Fees<br>AGM costs||793|5,812<br>1,692|
|Property maintenance<br>Professional<br>fees||368<br>10|475<br>10|
|Sundries||395|762|
|Designated<br>fund<br>(5048Anniversary)<br>Designated<br>fund (development)<br>Staffrecruitment<br>costs||629|837<br>1,088<br>160|
|||15@35|28,823|
|||374,883|312,030|





## 

## 

## 

## 

|The amount<br>paid in the year comprises:||||2020|2019|
|---|---|---|---|---|---|
|Research grants:<br>Dr Parastoo Babakinejad,<br>Royal Victoria Infirmary,|Newcastle||upon Tyne||6,750|
|Ms Ella Guest, University ofthe West ofEngland,|Bristol||||9,564|
|Dr David Hill, University ofSunderland||||9,916||
|Dr Alison Havelin, Royal Victoria, Newcastle||||10,000||
|PhD studentship<br>grants 2020:<br>Prof Silvia Bulfoue-Paus,<br>University ofManchester||||28,500||
|Prof Miriam Wittman,<br>University ofLeeds||||28,500||
|Dr Francesca Capon, Kings College, London||||28,500||
|PhD studentship<br>grants 2019:<br>Dr Paola Di Meglio, StJohns Institute ofDermatology,<br>London<br>Dr Daniele Bergamaschi,<br>Queen Maty University ofLondon||||28,500|28,500<br>28,500|
|PhD studentship<br>grants 2018:<br>Prof Nick Reynolds,<br>Neu)castle<br>University<br>Dr Henning<br>Holle, University of Hull<br>Dr Helen Young, University ofManchester||||28,500<br>28,500<br>28,500|28,500|
|PhD studentship<br>grants 2017:<br>Dr Francesca Capon, Kings CoBege, London<br>Prof Eugene Healy, Southampton<br>University<br>Dr Richard Warren, University ofManchester||||27,000|27,000<br>54,000<br>27,000|
|||||246,416|204,814|
|Reconciliation ofgrants payable:||||||
|||||2020|2019|
|Commitments<br>at 1January 2020 subject to the satisfaction of <br>conditions|||grant|283,500|306,000|
|Commitments<br>made ui the year subject to the satisfaction ofgrant<br>conditions<br>Grants payable during the year||||280,668<br>~246,416)|187,314<br> ~200,~I I)|
|Commitments<br>at 31December 2020 subject to the <br>ofgrant conditions|satisfaction|||317,752|283,500|





## 

## 

## 

|Commi|tment|s<br>are payable as follows:|||
|---|---|---|---|---|
||||2020|2019|
|Within <br>Within|one <br> two|yeat<br> years|142,500<br>175,252|112,500<br>171,000|
||||317,752|253,500|



## 

## 

|Staffcostsduringtheyear were as follows:|||
|---|---|---|
|||2019|
|Wages and salaries<br>Social security costs<br>Other pension costs|226,506<br>21,403<br>11,106|184,134<br>16,710<br>8,285|
||259,015|209,129|



## 



## 

## 

## 

## 

## 

## 

|Tangible fixed|assets||||
|---|---|---|---|---|
||||Fixtutes||
||||and|Freehold|
|||Total|Sttings|property|
|Cost or valuation|||||
|At 1January 2020<br>Revaluation||500,000<br>~5,0tltl)||500,000<br>(5,000)|
|||500,000||500,000|
|Depreciation|||||
|At 1January 2020|||||
|Provided during the year|||||
|Net book amount|at 31December 2020|495,000||495,000|
|Net book amount|at 31December 2019|500,000||500,000|



## 

## 

|Fixed asset|investmen|ts||||
|---|---|---|---|---|---|
||||No 1|No 2||
||||Portfolio|Portfolio|Total|
|Investments||||||
|Listed investments||||||
|Market value|at 1January|2020|2,765,921|2420326|5,186,247|
|Additions|||678,884|441,993|1,120,877|
|Disposals<br>Net unrealised|investment|gain|(656,062)<br>241,508|(403,297)<br>115,875|(1,059,359)<br>357,383|
|Market value|at 31December 2020||3,030,251|2,574,897|5,605,148|
|Market value|at 31December 2019||2,765,921|2,420,326|5,186,247|





## 

## 

## 

## 

## 


## 

|Historical cost at 31|Historical cost at 31|Historical cost at 31|December 201|December 201|9|2,253,1|9<br>2,132,925|9<br>2,132,925|4,386,|
|---|---|---|---|---|---|---|---|---|---|
|Realised gains/(losses)|||made during||the year on disposals|totalled|g (92,902)(2019$114,417)|||
|The investments||are|registered|as follows:||||||
||||||||Market|value||
|||||||No1|No 2|Total|Total|
||||||Portfolio||Portfolio|2020|2019|
|United Kingdom<br>Overseas|||||150013856<br>2,028@95||1,004,191<br>1870,706|2&006,047<br>3,599,101|2,778,262<br>2,407,985|
||||||3,030,251||2,574,897|5,605,148|5,186,247|
|Debtors||||||||||
|||||||||2020|2019|
|Investment|income|||||||18/98|21,626|
|Other debtors||||||||5@06|23,630|
|Prepayments||||||||4,630|9,466|
|||||||||23,334|54,722|





## 

## 

## 

## 

## 

|Creditors: amo|unts<br>fnllinE due within one year|||
|---|---|---|---|
|||2020|2019|
|Grants approved,<br>Other creditors|not yet paid|76,916<br>33186|63,750<br>2,169|
|Accruals||10,881|15,020|
|||90,903|80,939|



## 

## 

## 

## 

|||||Josie|||
|---|---|---|---|---|---|---|
|||||Bradbury|||
|||||Memorial|Research|Total|
|Permanent|Endowment||funds||||
|At 1January 2020<br>Unrealised<br>investment||gains||25,039|4,015,439<br>449,475|4,040,478<br>449,475|
|At 31December 2020||||25,039|4,464,914|4,489,953|





## 

## 

## 

|Restricted funds||||
|---|---|---|---|
||Research|Scotland|Total|
|At 1January 2020|622,959|65,272|688,231|
|Incoming resources|272,207|1,000|273,207|
|Expenditure|(246,416)|(555)|(246,971)|
|Transfers|(25,000)|(4,169)|(29,169)|
|At 31December 2020|623,750|61,548|685,298|



## 

## 

|||||||50th||
|---|---|---|---|---|---|---|---|
||Training|Development|Education|Research|ESTOP|Anniveraaty|Total|
|At 1January 2020<br>Expenditure|25,179<br>(1,166)|59,025<br>(8,820)|399,184<br>(10,320)|129,111<br>(10,380)<br>75,000|585,134|235,134<br>(235,134)|847,633<br>(30,686)<br>425,000|
|At 31December|24,013|50,205|388,864|193,731|585,134||1,241,947|
|2020||||||||





## 

## 

## 

## 

## 


## 

|Reconcgiation<br>ofnet movement<br>in fun|ds to net cash flow|from operating<br>ac|tivities|
|---|---|---|---|
|||2020|2019|
|Net movement<br>in funds||848,993|6,476,015|
|Interest and investment<br>income receivable||(109,842)|(134,314)|
|Net (gains) on investments<br>Donation<br>from fonuer charity||(357,383)|(677,769)<br>(5,918,633)|
|(Gain)/loss<br>on revaluation<br>offixed assets||5,000||
|Decrease/increase)<br>in debtors||26,388|(20,846)|
|Increase/(decrease)<br>in creditors||10,044|(66,584)|
|Net cash (used)/generated<br>from operating|activities|4c,20D|(342,131i|



## 



## 

## 

## 

## 

## 

## 

|Tangible fixed assets<br>Fixed asset investments|||500,000<br>4,602,573|
|---|---|---|---|
|Current assets|||963,583|
|Current liabilities|||~(147,523|
|Net assets|||5,918,633|
|These net assets were represented|by the following|funds:||
|Capital funds<br>Endowments|||3,477,126|
|Income funds||||
|Restricted<br>funds|||677,695|
|Unrestricted<br>funds:||||
|Property<br>fund<br>General funds|||500,000<br>302,632|
|Designated<br>funds|||961,180|
||||5,918,633|





## 

## 

## 



||||Cl<br>0 O||In <br>5|r00<br> rt|||~CI<br>0<br>In||CD<br>m<br>an|an||Ca|CI<br>'Cl<br>r'cr|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
||||||Ita|||||||||||
||||CD ~o 'OI|||||||||||Ita<br>cn|CD<br>r|
||||||||||rr||||||O|
||||||||||m|||||Ita|C0|
||||'000<br>I||It)0<br>r " <br>r|~ta<br>ata"<br>a0|Ca0<br>Ita|I|~n<br>00<br>00|||||||
||||FC|||||||||||||
||||||||||C0<br>CI|||||||
||||||Ca<br>C<br>CI<br>In||||CI<br>ca<br>~ra||||||Ca<br>CI<br>IDI|
|||Cl||||||||||||||
|||cr||||||||||||||
|||III||||||||||||||
||||||||||||~n|||||
|||||||||||||r|||~n<br>00|
||||||||||||||||r|
||||i8<br>0|||||||||||||
|||||||||||||Ctl|||CI<br>00|
|||'0<br>CI|||||||ICI<br>r|||CO|||rc<br>In<br>In|
||CD|C||||||||||||||
||COO|4l||||||||||||||
||CO|||||||||||||||
||Cf|||||||||||||||
||ta|||||||||||||||
||E|||||||||||||||
||Cl0|||||||||||||||
||CC|C<br>4I||||||||||||||
||Cl'000|~I0<br>W||||||||||||||
||C0<br>0|C0C<br>4IC|||||||a<br>Ol|||||||
||L0|0|||||||4C|||||CC||
|IO<br>IO<br>Ol<br>I<br>40<br>I|000CC<br>l7|C<br>4I<br>E<br>OI<br>l4~I<br>44<br>N||0<br>C<br>0<br>0 00<br>~4||jnj<br>c0 .Ca U<br>98 8<br>0 0<br>0<br>.C0 0 0<br>08<br>8<br>0<br>Ca<br>U<br>C 0 0|||9<br>0|0j <br>C|j:<br>00||C|h<br>C|80<br>I|